SLU-PP-332 dosage: reported doses and schedule
An exercise-mimicking research chemical with mouse benefits and no human dosing trials.
Also called: SLU PP 332, SLUPP332, SLUPP-332.
Exercise mimetics · Pan-estrogen-related receptor (ERRα/β/γ) agonist · Evidence: Animal studies only.
Typical reported dose: 250 mcg once a day, 8 weeks on, 3 weeks off
- 250 micrograms with long breaks: 250 micrograms daily; reported 8 weeks on, 3 weeks off. once daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
- 500 micrograms before cardio: 500 micrograms daily. once daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
- Split capsules, twice daily: 500 micrograms twice daily; total 1,000 micrograms per day. twice daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
- Corrected report: 250 three times: 250 micrograms three times daily; total 750 micrograms per day. three times daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
- 5 mg twice daily: 5 mg twice daily; total 10 mg per day. twice daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
- 60 mg reduced because of fatigue: 60 mg daily; later 40 mg morning + 20 mg pre-workout; then 20 mg morning. Later limited use to 3 sessions weekly. daily, then three training sessions per week, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to SLU-PP-332
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
- 5-amino-1MQ: An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
Sources
- 2027 Prohibited List: Summary of Changes, UK Anti-Doping · 2026
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.